<?xml version='1.0' encoding='utf-8'?>
<document id="26384089"><sentence text="Design Features of Drug-Drug Interaction Trials Between Antivirals and Oral Contraceptives." /><sentence text="The aim of this work was to explore the major design features of drug-drug interaction trials between antiviral medications (AVs) and oral contraceptives (OCs)" /><sentence text=" Information on these trials (n = 27) was collected from approved drug labels and clinical pharmacology reviews conducted by the U" /><sentence text="S" /><sentence text=" Food and Drug Administration" /><sentence text=" The primary objective of all trials was to evaluate changes in OC exposure following the coadministration of AVs" /><sentence text=" In addition, an evaluation of potential pharmacodynamic interaction was performed in 10 of these trials" /><sentence text=" Twenty-two trials were open label with a fixed-sequence design, and 5 trials used a double-blind crossover design" /><sentence text=" The trials were conducted using one, two, or three 28-day ovulatory cycles in 10, 8, and 9 trials, respectively" /><sentence text=" Only 1 trial enrolled HIV-infected women" /><sentence text=" The median number of women in a trial was 20 (range, 12 to 52)" /><sentence text=" Norethindrone/ethinyl estradiol (EE) combination was the most commonly used OC (n = 16, 59%) followed by norgestimate/EE (n = 9, 33%)"><entity charOffset="1-14" id="DDI-PubMed.26384089.s12.e0" text="Norethindrone" /><entity charOffset="15-32" id="DDI-PubMed.26384089.s12.e1" text="ethinyl estradiol" /><entity charOffset="34-36" id="DDI-PubMed.26384089.s12.e2" text="EE" /><entity charOffset="77-79" id="DDI-PubMed.26384089.s12.e3" text="OC" /><entity charOffset="106-118" id="DDI-PubMed.26384089.s12.e4" text="norgestimate" /><entity charOffset="119-130" id="DDI-PubMed.26384089.s12.e5" text="EE" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e0" e2="DDI-PubMed.26384089.s12.e5" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e1" e2="DDI-PubMed.26384089.s12.e1" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e1" e2="DDI-PubMed.26384089.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e1" e2="DDI-PubMed.26384089.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e1" e2="DDI-PubMed.26384089.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e1" e2="DDI-PubMed.26384089.s12.e5" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e2" e2="DDI-PubMed.26384089.s12.e2" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e2" e2="DDI-PubMed.26384089.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e2" e2="DDI-PubMed.26384089.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e2" e2="DDI-PubMed.26384089.s12.e5" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e3" e2="DDI-PubMed.26384089.s12.e3" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e3" e2="DDI-PubMed.26384089.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e3" e2="DDI-PubMed.26384089.s12.e5" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e4" e2="DDI-PubMed.26384089.s12.e4" /><pair ddi="false" e1="DDI-PubMed.26384089.s12.e4" e2="DDI-PubMed.26384089.s12.e5" /></sentence><sentence text=" Labeling recommendations were based on exposure changes in 25 cases and on safety observations in the trial in 2 cases" /><sentence text=" In conclusion, a wide variety of trial designs was used, and there is no preferred design" /><sentence text=" The answer to the exposure question can be achieved using multiple designs" /><sentence text=" " /></document>